- Home
- ANTX
as 06-20-2025 4:00pm EST
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 33.2M | IPO Year: | 2022 |
| Target Price: | $2.00 | AVG Volume (30 days): | 441.8K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $3.07 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of AN2 Therapeutics Inc. (ANTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | ANTX | 10% Owner | Jun 12 '25 | Sell | $1.09 | 200,000 | $218,000.00 | 3,017,432 | |
| Easom Eric | ANTX | Chief Executive Officer | Jun 2 '25 | Buy | $1.07 | 10,000 | $10,665.00 | 256,380 | |
| FitzPatrick Margaret M | ANTX | Director | May 28 '25 | Buy | $1.18 | 8,610 | $10,133.11 | 8,610 | |
| Leonard Braden Michael | ANTX | 10% Owner | May 28 '25 | Sell | $1.09 | 2,532,000 | $2,872,476.80 | 3,017,432 |
Latest AN2 Therapeutics Inc. News
ANTX Breaking Stock News: Dive into ANTX Ticker-Specific Updates for Smart Investing
Business Wire
24 days ago
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
Business Wire
a month ago
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Business Wire
2 months ago
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
Business Wire
2 months ago
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
Simply Wall St.
2 months ago
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Business Wire
4 months ago
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
Simply Wall St.
4 months ago
Golden Sun Health Technology Group Leads 3 US Penny Stocks Worth Monitoring
Business Wire
4 months ago
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
Compare ANTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANTX AN2 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.